IP Library Granted Patent US 10,864,276
Granted Patent B2
US 10,864,276 · App. 16/144,358 · Granted Dec 15, 2020

Activated polyoxazolines and conjugates and compositions comprising the same

Inventors: J Milton Harris (Huntsville, AL); Kunsang Yoon (Madison, AL); Michael David Bentley (Huntsville, AL); Zhihao Fang (Madison, AL); Tacey Viegas (Madison, AL); Francesco Maria Veronese (Padua, IT); Anna Mero (Padua, IT)
Assignee: Serina Therapeutics, Inc.
A61K47/59A61K31/727A61K31/728A61K38/10A61K38/1719A61K38/1816A61K38/193A61K38/27A61K38/33A61K38/42A61K38/47C07K7/08C07K14/47C07K14/505C07K14/535C07K14/62C08G69/48C12N9/96C12Y302/01017
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,864,276
App. No.
16/144,358
Granted
Dec 15, 2020
Kind
B2
Abstract

The present disclosure provides POZ derivatives having a range of active functional groups allowing conjugation of POZ derivatives to a variety of target molecules under a wide range of reaction conditions to produce a hydrolytically stable target molecule-POZ conjugate. Furthermore, the present disclosure provides novel methods of synthesis for the disclosed POZ derivatives and hydrolytically stable target molecule-POZ conjugates created using the disclosed terminally activated monofunctional POZ derivatives. In one embodiment, the POZ derivative is a terminally activated monofunctional POZ derivative.

Claims (28)

1. A terminally activated polyoxazoline (POZ) compound of the general structure R 1 -POZ-P p -Q q -W w -U u -X,

wherein

POZ is [N(COR 7 )CH 2 CH 2 ] n

X is an active functional group;

P is —O—;

q is 0;

p, u and w are each 1;

U is a linking group selected from the group consisting of: —(R 16 ) o —, —(CR 5 R 6 ) o —, —NH—R 21 —NHCO—R 22 —;

W is —NH—CO;

R 7 is independently selected for each repeating unit of POZ from an unsubstituted or substituted alkyl, alkenyl or aralkyl group;

R 1 , R 5 -R 6 and R 21 -R 22 are each independently selected from hydrogen, unsubstituted or substituted alkyl, alkenyl or aralkyl group;

R 16 is an unsubstituted alkyl, alkenyl or aralkyl group;

n is an integer from 3 to 1000; and

o is an integer from 1 to 10.

2. The terminally activated POZ compound of claim 1 , wherein the active functional group is protected.

3. The terminally activated POZ compound of claim 1 , wherein R 7 is an unsubstituted or substituted alkyl, alkenyl having from 1 to 12 carbon atoms.

4. The terminally activated POZ compound of claim 1 , wherein R 7 is methyl, ethyl or n-propyl.

5. The terminally activated POZ compound of claim 1 , wherein the active functional group is selected from the group consisting of: aldehyde, active carbonate (O—CO—Z), maleimide, sulfonate ester (OSO 2 —R 23 ), hydrazide, epoxide, iodoacetamide, alkyne, azide, isocyanate, cyanate isothiocyanate, thiocyanate, nitrile, a carbonyldiimidazole derivative, vinylsulfone, carboxylic acid halide, active ester (—CO—Z) and carboxylic acid, wherein any of the foregoing may be substituted or unsubstituted, Z is an activating group and R 23 is an unsubstituted or substituted alkyl, alkenyl, alkynyl, aralkyl or aryl group.

6. The terminally activated POZ compound of claim 5 , wherein the sulfonate ester is tresylate or mesylate.

7. The terminally activated POZ compound of claim 5 , wherein Z is N-succinimidyloxy, chlorine, bromine, sulfo-N-succinimidyloxy, p-nitrophenoxy, 1-imidazolyl, or 1-benzotriazolyloxy.

8. The terminally activated POZ compound of claim 5 , wherein the active functional group is a substituted or unsubstituted piperazinyl or a substituted piperidinyl group.

9. The terminally activated POZ compound of claim 1 , wherein the POZ polymer has a polydispersity value of less than or equal to 1.05.

10. The terminally activated POZ of claim 1 linked to a target molecule.

11. The terminally activated POZ compound of claim 1 , wherein the active functional group forms a linkage with a target molecule and wherein all linkages between the target molecule and the POZ compound are hydrolytically stable in a biological system.

12. A compound having a structure:

(a) CH 3 —[N(COCH 2 CH 3 )CH 2 CH 2 ] n —OCONH—CH 2 CH 2 —NH 2 ; or

(b) CH 3 —[N(COCH 2 CH 3 )CH 2 CH 2 ] n —OCONH—CH 2 —CHO

wherein, n is an integer from 3 to 1000.

Assignments (2)
CHANGE OF NAME Recorded Apr 8, 2024
From: SERINA THERAPEUTICS, INC.
To: SERINA THERAPEUTICS (AL), INC.
Reel/Frame 067036/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2020
From: HARRIS, J. MILTON; BENTLEY, MICHAEL DAVID; YOON, KUNSANG; FANG, ZHIHAO; VIEGAS, TACEY; VERONESE, FRANCESCO MARIA; MERO, ANNA
To: SERINA THERAPEUTICS, INC.
Reel/Frame 053747/0223 →
Continuity (11)
Continuation 15453686 · Mar 8, 2017
Continuation 14663863 · Mar 20, 2015
Continuation 13961576 · Aug 7, 2013
Continuation 13676048 · Nov 13, 2012
Continuation 13276910 · Oct 19, 2011
Continuation 12622264 · Nov 19, 2009
Continuation In Part 12529001
Provisional Application 61116246 · Nov 19, 2008
Provisional Application 61116252 · Nov 19, 2008
Provisional Application 60892212 · Feb 28, 2007
Related Publication 20190070301A1 · Mar 7, 2019